Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

https://doi.org/10.1016/j.bmcl.2010.02.024Get rights and content

Abstract

Protein kinase C (PKC) plays a major role in regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. Tamoxifen, a widely used breast cancer drug is known to inhibit PKC and demonstrate antimanic properties in human. We describe herein the synthesis of endoxifen, a tamoxifen active metabolite and compared its PKC inhibitory activity with that of tamoxifen. Endoxifen exhibited fourfold higher potency compared to tamoxifen.

Graphical abstract

A novel synthesis of endoxifen and its PKC inhibitory activity is reported.

  1. Download : Download full-size image

References and notes (11)

  • E. Friedman et al.

    Biol. Psychiatry

    (1993)
  • H. Einat et al.

    Biol. Psychiatry

    (2006)
    M. Narita et al.

    Neuroscience

    (2001)
  • J. Kulkarni et al.

    Psychoneuroendocrinology

    (2006)
    J.M. Bebchuk et al.

    Arch. Gen. Psychiatry

    (2000)
  • A. Yildiz et al.

    Arch. Gen. Psychiatry

    (2008)
    C.A. Zarate et al.

    Bipolar Disord.

    (2007)
  • N. DiazGranados et al.

    Curr. Psychiatry Rep.

    (2008)
There are more references available in the full text version of this article.

Cited by (0)

View full text